SAS Features Case Study of Extensive Relationship With Clearstone Central Laboratories
Clearstone Central Laboratories announced that business analytics software giant SAS has recently published a customer success story that features the extensive history between the two companies working alongside to accelerate clinical trails with clean, on-time data.
Every year, pharmaceutical companies deliver an ever-broadening range of medications that improve patient health and save countless lives. But the clinical trial phase of drug development is a risky proposition—expensive, highly regulated, and critical to the market approval of a drug. Increasingly, pharmaceutical executives are turning to Clearstone to manage this complex process of creating, aggregating, and delivering highly structured, reliable, and timely data.
SAS has allowed Clearstone to effectively work with large volumes of data that previously would require substantially more time and resources. Multiple tasks can be run simultaneously, allowing for time efficiencies. This additional flexibility has enabled Clearstone to rapidly scale its business around the world and expand its service offering to include data mining and analytical services that allow Clearstone to predict aspects of a trial using historical data.
- Podcast interview with Hacene Mekerri
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
